Topotecan in combination with CQ increased the anti-tumor effects in the HCT116 p53+/+ xenograft model over that of topotecan alone; in contrast the inclusion of CQ seemed to impair the anti-tumor activity of topotecan in the HCT116 p53−/− model. This evidence concerns the gene TP53 and neoplasm.